Biotech by today's price change
How far the share price has moved since the previous close.
Repligen leads the 24 biotech ranked by today's price change, at +4.87%, ahead of CRISPR Therapeutics (+4.60%) and Scholar Rock Holding (+3.39%). Figures as of 18 Nov 2026, 14:43 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- Repligen+4.87%
- Median
- +0.30%
- Combined market value
- AED 3.11T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Today ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | RepligenRGEN · Health Care | +4.87% | AED 39.9B | AED 624.65 | 4.87% up | 5% up | ||
| 2 | CRISPR TherapeuticsCRSP · Health Care | +4.60% | AED 15B | AED 154.24 | 4.60% up | 21% down | ||
| 3 | Scholar Rock HoldingSRRK · Health Care | +3.39% | AED 20.9B | AED 171.18 | 3.39% up | 14% up | ||
| 4 | argenxARGX · Health Care | +1.34% | AED 221.8B | AED 3,526.39 | 1.34% up | 4% up | ||
| 5 | Krystal BiotechKRYS · Health Care | +1.31% | AED 32.9B | AED 1,110.78 | 1.31% up | 46% up | ||
| 6 | Twist BioscienceTWST · Health Care | +1.18% | AED 28.4B | AED 416.18 | 1.18% up | 340% up | ||
| 7 | Kymera TherapeuticsKYMR · Health Care | +1.03% | AED 38.5B | AED 450.89 | 1.03% up | 87% up | ||
| 8 | Adaptive BiotechnologiesADPT · Health Care | +0.95% | AED 17.1B | AED 105.62 | 0.95% up | 88% up | ||
| 9 | ImmunovantIMVT · Health Care | +0.93% | AED 25.5B | AED 123.11 | 0.93% up | 43% up | ||
| 10 | CG OncologyCGON · Health Care | +0.56% | AED 26B | AED 291.53 | 0.56% up | 85% up | ||
| 11 | BiogenBIIB · Health Care | +0.41% | AED 136.7B | AED 924.83 | 0.41% up | 49% up | ||
| 12 | BioNTechBNTX · Health Care | +0.30% | AED 77.5B | AED 312.59 | 0.30% up | 16% down | ||
| 13 | ModernaMRNA · Health Care | +0.30% | AED 308.2B | AED 761.77 | 0.30% up | 755% up | ||
| 14 | Halozyme TherapeuticsHALO · Health Care | +0.27% | AED 40.3B | AED 353.40 | 0.27% up | 37% up | ||
| 15 | Bio-TechneTECH · Health Care | +0.13% | AED 42B | AED 267.09 | 0.13% up | 26% up | ||
| 16 | ExelixisEXEL · Health Care | +0.11% | AED 61.5B | AED 251.85 | 0.11% up | 63% up | ||
| 17 | QiagenQGEN · Health Care | -0.06% | AED 37.7B | AED 182.60 | 0.06% down | 12% up | ||
| 18 | Neurocrine BiosciencesNBIX · Health Care | -0.19% | AED 61.6B | AED 608.18 | 0.19% down | 20% up | ||
| 19 | VaxcytePCVX · Health Care | -0.29% | AED 34.4B | AED 217.51 | 0.29% down | 22% up | ||
| 20 | Gilead SciencesGILD · Health Care | -0.34% | AED 772.9B | AED 623.17 | 0.34% down | 33% up | ||
| 21 | Kodiak SciencesKOD · Health Care | -0.39% | AED 23.2B | AED 354.11 | 0.39% down | 396% up | ||
| 22 | ImmunityBioIBRX · Health Care | -0.64% | AED 24.3B | AED 22.84 | 0.64% down | 193% up | ||
| 23 | Revolution MedicinesRVMD · Health Care | -0.74% | AED 128.3B | AED 593.07 | 0.74% down | 131% up | ||
| 24 | AmgenAMGN · Health Care | -1.10% | AED 899.7B | AED 1,663.25 | 1.10% down | 34% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 3.6726 AED).
Questions and answers
Which biotech rank first by today's price change?
Repligen (+4.87%), CRISPR Therapeutics (+4.60%) and Scholar Rock Holding (+3.39%) are the top three of the 24 biotech ranked by today's price change as of 18 Nov 2026, 14:43 UTC.
How many biotech are in this ranking?
24 are ranked by today's price change.
What are these biotech worth together?
The 24 biotech ranked by today's price change have a combined market value of AED 3.11T as of 18 Nov 2026, 14:43 UTC.
What does ranking by today's price change measure?
How far the share price has moved since the previous close.
Learn how this ranking works
All markets guides →- 52-week high and low: what the range tells you
A stock's 52-week high and low are the highest and lowest prices it reached over the past year. Where today's price sits in that range, from 0% at the low to 100% at the high, shows how the past year has gone. Sources differ on whether they use closing or intraday prices, so the same stock's range can differ slightly.
- Drawdown and recovery: why a 50% fall needs a 100% gain
A drawdown is how far a price has fallen from its previous peak, as a percentage of that peak. Recovery needs a larger gain than the fall, because the gain starts from a smaller base: a 20% drop needs a 25% rise to get back, a 50% drop needs 100%, and a 75% drop needs 300%.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Biotech by today's price change”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=day-change
Underlying data: Yahoo Finance; SEC EDGAR.